Avanzanite Bioscience
Privately held: no public share price · Netherlands
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Mitapivat(Pyrukynd) | Approved | Pyruvate kinaseSmall molecule | Sickle Cell DiseasePyruvate Kinase DeficiencyBeta-Thalassemia Transfusion-Dependent Beta Thalassemia |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (3)
March 2029 (1)
Mitapivat · PyrukyndPhase 3Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Est. primary completion 2029-03 · NCT07517133 · CT.gov ↗
What to watch
June 2029 (1)
Mitapivat · PyrukyndPhase 3Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia
Est. primary completion 2029-06 · NCT07506863 · CT.gov ↗
What to watch
August 2029 (1)
Est. primary completion 2029-08 · NCT07656415 · CT.gov ↗
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
US, FDA · AGIOS PHARMACEUTICALS, INC. · Source ↗
Financial reports
No financial reports recorded.